Mans, D R A, Kent, A D, Hu, R V, Lai A Fat, E J, Schoone, G J, Adams, Emily ORCID: https://orcid.org/0000-0002-0816-2835, Rood, E J, Alba, S, Sabajo, L O A, Lai A Fat, R F, de Vries, H J C and Schallig, H D F H (2015) 'Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.'. Clinical and experimental dermatology, Vol 41, Issue 6, pp. 610-615.
Full text not available from this repository.Abstract
BACKGROUND
Leishmania (Viannia) guyanensis is believed to be the principal cause of cutaneous leishmaniasis (CL) in Suriname. This disease is treated with pentamidine isethionate (PI), but treatment failure has increasingly been reported.
AIM
To evaluate PI for its clinical efficacy, to compare parasite load, and to assess the possibility of treatment failure due to other infecting Leishmania species.
METHODS
Parasite load of patients with CL was determined in skin biopsies using real-time quantitative PCR before treatment and 6 and 12 weeks after treatment. Clinical responses were evaluated at week 12 and compared with parasite load. In parallel, molecular species differentiation was performed.
RESULTS
L. (V.) guyanensis was the main infecting species in 129 of 143 patients (about 90%). PI treatment led to a significant decrease (P < 0.001) in parasite counts, and cured about 75% of these patients. Treatment failure was attributable to infections with Leishmania (Viannia) braziliensis, Leishmania (Leishmania) amazonensis and L. (V.) guyanensis (1/92, 1/92 and 22/92 evaluable cases, respectively). There was substantial agreement beyond chance between the parasite load at week 6 and the clinical outcome at week 12, as indicated by the κ value of 0.61.
CONCLUSIONS
L. (V.) guyanensis is the main infecting species of CL in Suriname, followed by L. (V.) braziliensis and L. (L.) amazonensis. Furthermore, patient response to PI can be better anticipated based on the parasite load 6 weeks after the treatment rather than on parasite load before treatment.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | NOT_LSTM |
Subjects: | QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified. QX Parasitology > Protozoa > QX 70 Mastigophora. (e.g., Giardia. Trichomonas. Trypanosoma. Leishmania) WR Dermatology > Parasitic Skin Diseases > WR 350 Tropical diseases of the skin. Mucocutaneous leishmaniasis. Leishmaniasis |
Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology |
Digital Object Identifer (DOI): | https://doi.org/10.1111/ced.12786 |
Depositing User: | Mary Creegan |
Date Deposited: | 17 Feb 2016 11:37 |
Last Modified: | 05 Nov 2024 12:43 |
URI: | https://archive.lstmed.ac.uk/id/eprint/5656 |
Statistics
Actions (login required)
Edit Item |